UK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest birch allergy product failed to reduce symptoms.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.